Mabqi
Mabqi is a biotechnology company specializing in the discovery and development of fully human antibodies using an AI-powered antibody discovery platform. Their core technology includes the HuscI2™ suite of fully human synthetic antibody libraries combined with AI-driven phage and yeast display technologies, enabling discovery of therapeutic antibodies such as monoclonal antibodies (mAbs), multispecific antibodies, pH-sensitive antibodies, and antibody-drug conjugates (ADCs). Mabqi focuses on challenging targets including transmembrane proteins, ion channels, and peptides, with a robust pipeline in oncology. The company collaborates through partnerships and licensing, leveraging its proprietary libraries and know-how to accelerate antibody-based therapy development. Mabqi is headquartered in Montpellier, France, with a team of experienced scientists and industry professionals, and has received innovation awards such as i-Lab 2018 and Les Inn’Ovations 2022.
Mabqi
Mabqi is a biotechnology company specializing in the discovery and development of fully human antibodies using an AI-powered antibody discovery platform. Their core technology includes the HuscI2™ suite of fully human synthetic antibody libraries combined with AI-driven phage and yeast display technologies, enabling discovery of therapeutic antibodies such as monoclonal antibodies (mAbs), multispecific antibodies, pH-sensitive antibodies, and antibody-drug conjugates (ADCs). Mabqi focuses on challenging targets including transmembrane proteins, ion channels, and peptides, with a robust pipeline in oncology. The company collaborates through partnerships and licensing, leveraging its proprietary libraries and know-how to accelerate antibody-based therapy development. Mabqi is headquartered in Montpellier, France, with a team of experienced scientists and industry professionals, and has received innovation awards such as i-Lab 2018 and Les Inn’Ovations 2022.